Peptide·modified or textual
Tirzepatide
ATLPC0005195
Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Routes
- Length43 aa
Stack
ATLPC0005195
Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
What safety, toxicity, or tolerability evidence is attached?
Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.
Features are shown only when a reported notation or topology record supports them.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token b is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token b is not one of the 20 standard residue symbols in this display.
Normalized for positional visualization, not a replacement for the reported modified notation.
YAIXEGTFTSDYSIAIXLDKIAQKAFVQWLIAGGPSSGAPPPS
Original notation retained for interpretation and comparison.
Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Interpretation: Evidence should be compared across compatible peptide identities and peptidoforms. A sequence-only match may not be equivalent when terminal modifications, stereochemistry, cyclization, or cross-links differ.
YAIXEGTFTSDYSIAIXLDKIAQKAFVQWLIAGGPSSGAPPPSPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 80 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · bioavailability single percent · The mean absolute b... | Open |
| 2 | 80 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · bioavailability single percent · The mean absolute b... | Open |
| 3 | 80 % | Comparable | PepTherDia curated product PK field | Route: SC · 112 · Tirzepatide · exact product name match · field mismatch | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 35123 ng*h/mL | Comparable | AUC (0 to 168 hrs) in Beagle dog at 10 nmol/kg, sc administered as single dose and measured upto 168 hrs by LC-MS/MS analysis · dog | Route: sc · area under curve · AUC· AUC (0 to 168 hrs) in Beagle dog at 10 nmol/kg, sc administered a... | Open |
| 2 | Observation Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · exposure injection site similarity text · Similar ex... | Open |
| 3 | Observation Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · exposure injection site similarity text · Similar ex... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.344 μg/mL | Comparable | Cmax in Beagle dog at 10 nmol/kg, sc administered as single dose and measured upto 168 hrs by LC-MS/MS analysis · dog | Route: sc · max concentration · Cmax· Cmax in Beagle dog at 10 nmol/kg, sc administered as single dos... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 24 hours 86400 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · tmax median time range to max plasma concentration ·... | Open |
| 2 | 8-72 hours 28800-259200 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · tmax range median time to max plasma concentration ·... | Open |
| 3 | 8-72 hours 28800-259200 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · tmax range time to maximum · Absorption Following su... | Open |
| 4 | 14 hr 50400 seconds | Comparable | Tmax in Beagle dog at 10 nmol/kg, sc administered as single dose and measured upto 168 hrs by LC-MS/MS analysis · dog | Route: sc · time to max concentration · Tmax· Tmax in Beagle dog at 10 nmol/kg, sc administered as si... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 11.8 L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · volume of distribution apparent ss tirzepatide osa a... | Open |
| 2 | ~ 9.7 L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · volume of distribution apparent ss tirzepatide overw... | Open |
| 3 | ~ 10.3 L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Tirzepatide· 12.3 Pharmacokinetics · volume of distribution single · Distribution The mea... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 99 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Tirzepatide· 12.3 Pharmacokinetics · plasma binding bound to plasma matrix · Tirzepatide... | Open |
| 2 | 99 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Tirzepatide· 12.3 Pharmacokinetics · plasma binding bound to plasma matrix · Tirzepatide... | Open |
| 3 | 99 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: SC · 112 · Tirzepatide · exact product name match · field mismatch | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Serum/plasma stability and protease stability evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 116 Hours 417600 seconds | Comparable | HRAM LC/MS · human · Human plasma | Route: SC · Dose/window: 0.25 mg · Time: Blood samples for PK assessment of LY3298176 in the SAD part were collected at predose, 8, 24, 48, 72, 96, 12... · Human plasma protease · In Vivo | Open |
| 2 | 124 Hours 446400 seconds | Comparable | HRAM LC/MS · human · Human plasma | Route: SC · Dose/window: 0.5 mg · Time: Blood samples for PK assessment of LY3298176 in the SAD part were collected at predose, 8, 24, 48, 72, 96, 12... · Human plasma protease · In Vivo | Open |
| 3 | 106 Hours 381600 seconds | Comparable | HRAM LC/MS · human · Human plasma | Route: SC · Dose/window: 1 mg · Time: Blood samples for PK assessment of LY3298176 in the SAD part were collected at predose, 8, 24, 48, 72, 96, 12... · Human plasma protease · In Vivo | Open |
| 4 | 120 Hours 432000 seconds | Comparable | HRAM LC/MS · human · Human plasma | Route: SC · Dose/window: 2.5 mg · Time: Blood samples for PK assessment of LY3298176 in the SAD part were collected at predose, 8, 24, 48, 72, 96, 12... · Human plasma protease · In Vivo | Open |
| 5 | 123 Hours 442800 seconds | Comparable | HRAM LC/MS · human · Human plasma | Route: SC · Dose/window: 5 mg · Time: Blood samples for PK assessment of LY3298176 in the SAD part were collected at predose, 8, 24, 48, 72, 96, 12... · Human plasma protease · In Vivo | Open |
| 6 | 111 Hours 399600 seconds | Comparable | HRAM LC/MS · human · Human plasma | Route: SC · Dose/window: 8 mg · Time: Blood samples for PK assessment of LY3298176 in the SAD part were collected at predose, 8, 24, 48, 72, 96, 12... · Human plasma protease · In Vivo | Open |
| 7 | 482400 seconds | Comparable | LC-MS · dog · Beagle dogs plasma | Dose/window: 3 mg · Beagle dogs plasma protease · In Vivo | Not linked |
| 8 | 70 Hours 252000 seconds | Comparable | LC-MS · dog · Dogs plasma | Route: IV · Dose/window: 4.15 nmol/kg · Time: Blood sample collected over 336 Hours · Dogs plasma protease · In Vivo | Not linked |
| 9 | 97 Hours 349200 seconds | Comparable | LC-MS · dog · Dogs plasma | Route: Oral dose · Dose/window: 20 mg · Time: Blood sample collected over 336 Hours · Dogs plasma protease · In Vivo | Not linked |
| 10 | 159 Hours 572400 seconds | Comparable | LC-MS · dog · Dogs plasma | Route: SC · Dose/window: 4.15 nmol/kg · Time: Blood sample collected over 336 Hours · Dogs plasma protease · In Vivo | Not linked |
Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.061 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Tirzepatide· 12.3 Pharmacokinetics · clearance single · Elimination The apparent populati... | Open |
| 2 | ~ 0.06 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Tirzepatide· 12.3 Pharmacokinetics · clearance single · Elimination The apparent populati... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
PubMed 35651477 | Stability Serum Plasma Stability | No reported alias Y-Aib-EGTFTSDYSI-Ai...AFVQWLIAGGPSSGAPPPSexact | 6 identity 6 evidence |
PubMed 35674880 | Stability Serum Plasma Stability | No reported alias Y-Aib-EGTFTSDYSI-Ai...AFVQWLIAGGPSSGAPPPSexact | 4 identity 4 evidence |
Reference link | DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Plasma Protein Binding +2 more | No reported alias | 0 identity 8 evidence |
PubMed 35807558 | Stability Serum Plasma Stability | No reported alias Y-Aib-EGTFTSDYSI-Ai...AFVQWLIAGGPSSGAPPPSexact | 3 identity 3 evidence |
Reference link | DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Plasma Protein Binding +2 more | No reported alias | 0 identity 6 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias Y-Aib-EGTFTSDYSI-Ai...AFVQWLIAGGPSSGAPPPSexact | 1 identity 2 evidence |
PubMed 38330849 | Exposure Area Under Curve, Max Concentration, Time To Max Concentration | No reported alias | 0 identity 3 evidence |
PubMed 38356317 | Stability Serum Plasma Stability | No reported alias Y-Aib-EGTFTSDYSI-Ai...AFVQWLIAGGPSSGAPPPSexact | 1 identity 1 evidence |
Not linked Not linked | Stability Serum Plasma Stability | No reported alias Y-Aib-EGTFTSDYSI-Ai...AFVQWLIAGGPSSGAPPPSexact | 1 identity 1 evidence |
Not linked Not linked | Stability Serum Plasma Stability | No reported alias Y-Aib-EGTFTSDYSI-Ai...AFVQWLIAGGPSSGAPPPSexact | 1 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0005195' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.